



Stabilis



Epinephrine hydrochloride



Noms commerciaux

| | |
|----------------------|---|
| Adrenalin | Allemagne, Canada, Danemark, Espagne, Finlande, Islande, Luxembourg, Norvège, Suède, Suisse, Turquie |
| Adrenalina | Argentine, Colombie, Espagne, Portugal, Roumanie |
| Adrenaline | Arabie Saoudite, Egypte, France, Nouvelle Zélande |
| Anapen | Allemagne, Autriche, France, Grande Bretagne, Pays bas, Suède, Suisse |
| Emerade | Allemagne, Roumanie |
| Epipen | Argentine, Autriche, Belgique, Canada, Danemark, Etats Unis d'Amérique, Finlande, Grande Bretagne, Norvège, Nouvelle Zélande, Pays bas, Suède, Suisse |
| L - Adrenalin | Autriche |
| Levophed | Grèce |
| Levopress | Vénézuela |
| Min I Ject Adrenalin | Grande Bretagne |
| Pinadrina | Mexique |
| Suprarenin | Allemagne, Autriche |
| Tonogen | Hongrie |
| Vasocon | Inde |



Stabilité des solutions

| | | 100 µg/ml | 25°C | | 7 | | | 659 |
|--|--|-----------|---------|--|----|--|--|------|
| | | 100 µg/ml | 25°C | | 7 | | | 659 |
| | | 700 µg/ml | 25°C | | 56 | | | 659 |
| | | 700 µg/ml | 25°C | | 56 | | | 659 |
| | | 16 µg/ml | 23-25°C | | 45 | | | 4026 |
| | | 16 µg/ml | 3-5°C | | 60 | | | 4026 |
| | | 64 µg/ml | 23-25°C | | 45 | | | 4026 |

| | | | | | | | | | |
|--|--|-----------|---------|--|-----|--|--|--|------|
| | | 64 µg/ml | 3-5°C | | 60 | | | | 4026 |
| | | 100 µg/ml | 23°C | | 24 | | | | 192 |
| | | 16 µg/ml | 5°C | | 20 | | | | 197 |
| | | 100 µg/ml | 25°C | | 7 | | | | 659 |
| | | 700 µg/ml | 25°C | | 56 | | | | 659 |
| | | 20 µg/ml | 23°C | | 84 | | | | 3712 |
| | | 300 µg/ml | 23°C | | 84 | | | | 3712 |
| | | 900 µg/ml | 23°C | | 84 | | | | 3712 |
| | | 10 µg/ml | 2-8°C | | 90 | | | | 4323 |
| | | 10 µg/ml | 20-25°C | | 12 | | | | 4778 |
| | | 10 µg/ml | 25°C | | 21 | | | | 4393 |
| | | 10 µg/ml | 4°C | | 56 | | | | 4393 |
| | | 10 µg/ml | 4°C | | 56 | | | | 4778 |
| | | 20 µg/ml | 2-8°C | | 183 | | | | 3445 |
| | | 20 µg/ml | 2-8°C | | 180 | | | | 3397 |
| | | 20 µg/ml | 23°C | | 84 | | | | 3712 |
| | | 300 µg/ml | 23°C | | 84 | | | | 3712 |
| | | 900 µg/ml | 23°C | | 84 | | | | 3712 |
| | | 100 µg/ml | 2-8°C | | 172 | | | | 3309 |
| | | 100 µg/ml | 25°C | | 30 | | | | 3704 |
| | | 100 µg/ml | 4°C | | 30 | | | | 3704 |
| | | 25 µg/ml | 25°C | | 30 | | | | 3704 |
| | | 25 µg/ml | 4°C | | 30 | | | | 3704 |
| | | 50 µg/ml | 25°C | | 30 | | | | 3704 |
| | | 50 µg/ml | 4°C | | 30 | | | | 3704 |



Stabilité en mélange

| | | 2 & 100 µg/ml | 20°C-25°C | | Tirofiban : 50 µg/ml | 4 | | 1603 |
|--|----|---------------|-----------|--|-------------------------------|---|--|------|
| | | 0,1 µg/ml | 23°C | | Cefpirome sulfate : 50 mg/ml | 8 | | 280 |
| | | 0,03 µg/ml | 22°C-23°C | | Milrinone lactate : 0,2 mg/ml | 4 | | 813 |
| | RL | 0,1 µg/ml | 23°C | | Cefpirome sulfate : 50 mg/ml | 8 | | 280 |

| | | | | | | | | |
|--|--|--------------|---------|--|--|-----|--|------|
| | | 0,1 µg/ml | 23°C | | Cefpirome sulfate : 50 mg/ml | 8 | | 280 |
| | | 0,0006 µg/ml | 30°C | | Bupivacaine hydrochloride : 0,43 mg/ml Fentanyl citrate : 1,25 µg/ml | 48 | | 217 |
| | | 0,0006 µg/ml | 3°C | | Bupivacaine hydrochloride : 0,43 mg/ml Fentanyl citrate : 1,25 µg/ml | 20 | | 217 |
| | | 2 µg/ml | 18-22°C | | Fentanyl citrate : 2 µg/ml Bupivacaine hydrochloride : 1 mg/ml | 184 | | 2306 |
| | | 2 µg/ml | 4°C | | Bupivacaine hydrochloride : 1 mg/ml Fentanyl citrate : 2 µg/ml | 184 | | 2306 |
| | | 3,5 µg/ml | 22°C | | Lidocaine hydrochloride : 3,5 mg/ml Bleomycin sulfate : 0,75 mg/ml | 1 | | 3420 |
| | | 3,5 µg/ml | 4°C | | Lidocaine hydrochloride : 3,5 mg/ml Bleomycin sulfate : 0,75 mg/ml | 3 | | 3420 |
| | | 2 µg/ml | 22°C | | Fentanyl citrate : 2 µg/ml Bupivacaine hydrochloride : 1 mg/ml | 180 | | 1875 |
| | | 9 µg/ml | 4-7°C | | Lidocaine hydrochloride : 9 mg/ml Sodium bicarbonate : 7,8 mg/ml | 7 | | 2878 |
| | | 9 µg/ml | 4-7°C | | Lidocaine hydrochloride : 18 mg/ml Sodium bicarbonate : 7,8 mg/ml | 7 | | 2878 |
| | | 2 µg/ml | 4°C | | Fentanyl citrate : 2 µg/ml Bupivacaine hydrochloride : 1 mg/ml | 180 | | 1875 |
| | | 32 µg/ml | 25°C | | Calcium chloride : 4 mg/ml | 26 | | 3622 |
| | | 2 µg/ml | 20-24°C | | Fentanyl citrate : 4,1 µg/ml Levobupivacaine hydrochloride : 0,56 mg/ml | 40 | | 3401 |
| | | 2 µg/ml | 20-24°C | | Fentanyl citrate : 4,1 µg/ml Levobupivacaine hydrochloride : 0,56 mg/ml | 48 | | 3401 |
| | | 2 µg/ml | 4-8°C | | Fentanyl citrate : 4,1 µg/ml Levobupivacaine hydrochloride : 0,56 mg/ml | 60 | | 3401 |







Facteur influençant la stabilité

| | | | | |
|--|--------|--|--|--------------|
| | | | | 1965 2089 |
| | | | | 3401 |
| | | | | 197 |
| | | | | 3642 |
| | | | | 2306 |
| | PH >7 | | | 3642 |
| | PH > 6 | | | 197 |





























Compatibilités

| |  |  |  |
|---|---|--|---|
| <input checked="" type="checkbox"/> | Epinephrine hydrochloride : 16>>>32 µg/ml | Normo Sol® | 4655 |
| <input checked="" type="checkbox"/> | Epinephrine hydrochloride : 1000 µg/ml | RL | 4603 |
| <input checked="" type="checkbox"/> | Epinephrine hydrochloride : 0,2 µg/ml Alprostadil : 20 µg/ml | ◆ | 4491 |
| <input checked="" type="checkbox"/> | Epinephrine hydrochloride : 200 µg/ml Alprostadil : 20 µg/ml | ◆ | 4651 |
| <input checked="" type="checkbox"/> | Epinephrine hydrochloride : 1000 µg/ml Amiodarone hydrochloride : 6 mg/ml | ◆ | 1611 |
| <input checked="" type="checkbox"/> | Epinephrine hydrochloride : 1000 µg/ml Amoxicillin sodium / clavulanic acid : 100/10 mg/ml | | 3824 |
| <input checked="" type="checkbox"/> | Epinephrine hydrochloride : 50 µg/ml Anidulafungin : 0.5 mg/ml | ◆ | 1982 |
| <input checked="" type="checkbox"/> | Epinephrine hydrochloride : 4 µg/ml Atracurium besylate : 0.5 mg/ml | ◆ | 402 |
| <input checked="" type="checkbox"/> | Epinephrine hydrochloride : 100 µg/ml Caffeine : 10 mg/ml | ∅ | 3964 |
| <input checked="" type="checkbox"/> | Epinephrine hydrochloride : 0,05 µg/ml Caspofungin acetate : 0,7 mg/ml | ▲ | 2247 |
| <input checked="" type="checkbox"/> | Epinephrine hydrochloride : 16 µg/ml Cefiderocol sulfate tosylate : 20 mg/mL | ▲◆ | 4528 |
| <input checked="" type="checkbox"/> | Epinephrine hydrochloride : 100 µg/ml Cefpirome sulfate : 50 mg/ml | ▲◆ | 280 |
| <input checked="" type="checkbox"/> | Epinephrine hydrochloride : 50 µg/ml Ceftazidime : 125 mg/ml | 💧 | 2141 |
| <input checked="" type="checkbox"/> | Epinephrine hydrochloride : 16 µg/ml Ceftolozane / tazobactam : 10/5 mg/ml | ▲◆ | 3828 |
| <input checked="" type="checkbox"/> | Epinephrine hydrochloride : 0.1 µg/ml Cimetidine hydrochloride : 3 mg/ml | ◆ | 1201 |
|  | <input type="checkbox"/> Epinephrine hydrochloride : 1 & 10 µg/ml | NaH CO ₃ | 2077 |
| <input checked="" type="checkbox"/> | Epinephrine hydrochloride : 50 µg/ml Bivalirudin : 5 mg/ml | ◆ | 1713 |
| <input checked="" type="checkbox"/> | Epinephrine hydrochloride : 32 µg/ml Calcium chloride : 4 mg/ml | ▲ | 3622 |
| <input checked="" type="checkbox"/> | Epinephrine hydrochloride : 0.032 µg/ml Calcium chloride : 20 mg/ml | ◆ | 4732 |
| <input checked="" type="checkbox"/> | Epinephrine hydrochloride : 0.064 µg/ml Calcium chloride : 20 mg/ml | ◆ | 4732 |
| <input checked="" type="checkbox"/> | Epinephrine hydrochloride : 100 µg/ml Cefpirome sulfate : 50 mg/ml | ▲ 0.43 | 280 |
| <input checked="" type="checkbox"/> | Epinephrine hydrochloride : 50 µg/ml Cisatracurium besylate : 0.1 >> 5 mg/ml | ◆ | 299 |
| | <input type="checkbox"/> Epinephrine hydrochloride | NaH CO ₃ | 3642 |
| <input checked="" type="checkbox"/> | Epinephrine hydrochloride : 100 µg/ml Cefpirome sulfate : 50 mg/ml | RL | 280 |

| | | | |
|---|---|--|------|
|  | Epinephrine hydrochloride : 20 µg/ml Clonidine hydrochloride : 0,018 mg/ml |  | 2018 |
|  | Epinephrine hydrochloride : 9.6 µg/ml |  | 3379 |
|  | Epinephrine hydrochloride : 200 µg/ml |  | 939 |
|  | Epinephrine hydrochloride : 100 µg/ml Cloxacillin sodium : 100 mg/ml |  | 3012 |
|  | Epinephrine hydrochloride : 1000 µg/ml Cloxacillin sodium : 100 mg/ml |  | 3012 |
|  | Epinephrine hydrochloride : 50 µg/ml Dexmedetomidine : 4 µg/ml |  | 1712 |
|  | Epinephrine hydrochloride : 1000 µg/ml Diatrizoate meglumine : 283 mg/ml |  | 1085 |
|  | Epinephrine hydrochloride : 20 µg/ml Diltiazem hydrochloride : 1 mg/ml | | 314 |
|  | Epinephrine hydrochloride : 4 µg/ml Diltiazem hydrochloride : 5 mg/ml |  | 198 |
|  | Epinephrine hydrochloride : 50 µg/ml Diltiazem hydrochloride : 1 & 5 mg/ml |  | 198 |
|  | Epinephrine hydrochloride : 0.1 µg/ml Dobutamine hydrochloride : 2 mg/ml |  | 1041 |
|  | Epinephrine hydrochloride : 20 µg/ml Dobutamine hydrochloride : 4 mg/ml | | 314 |
|  | Epinephrine hydrochloride : 20 µg/ml Dopamine hydrochloride : 3.2 mg/ml | | 314 |
|  | Epinephrine hydrochloride : 16 µg/ml Eravacycline : 0,6 mg/ml |  | 4434 |
|  | Epinephrine hydrochloride : 128 µg/ml Esmolol hydrochloride : 10 mg/ml |  | 3879 |
|  | Epinephrine hydrochloride : 40 µg/ml Esomeprazole sodium : 0.32 mg/ml |  | 1506 |
|  | Epinephrine hydrochloride : 4 µg/ml Famotidine : 0.2 mg/ml |  | 398 |
|  | Epinephrine hydrochloride : 50 µg/ml Fenoldopam mesylate : 80 µg/ml |  | 1803 |
|  | Epinephrine hydrochloride : 20 µg/ml Fentanyl citrate : 50 µg/ml | | 314 |
|  | Epinephrine hydrochloride : 8 µg/ml Flucloxacillin sodium : 20 mg/ml |  | 1232 |
|  | Epinephrine hydrochloride : 16 µg/ml Fosfomycin : 30 mg/ml |  | 4055 |
|  | Epinephrine hydrochloride : 16 & 100 µg/ml Furosemide : 10 mg/ml |  | 4570 |
|  | Epinephrine hydrochloride : 20 µg/ml Furosemide : 10 mg/ml | | 314 |
|  | Epinephrine hydrochloride : 200 µg/ml Furosemide : 10 mg/ml |  | 3210 |
|  | Epinephrine hydrochloride : 8 µg/ml Furosemide : 1 mg/ml |  | 1232 |
|  | Epinephrine hydrochloride : 16 & 100 µg/ml Furosemide : 1 mg/ml |  | 4570 |
|  | Epinephrine hydrochloride : 20 µg/ml Heparin sodium : 100 UI/ml | | 314 |

| | | | | |
|-------------------------------------|-------------------------------------|--|----|------|
| <input checked="" type="checkbox"/> | <input checked="" type="checkbox"/> | Epinephrine hydrochloride : 100 µg/ml Heparin sodium : 1 UI/ml | | 1228 |
| <input checked="" type="checkbox"/> | <input checked="" type="checkbox"/> | Epinephrine hydrochloride : 100 µg/ml Heparin sodium : 1 UI/ml | RL | 1228 |
| <input checked="" type="checkbox"/> | <input checked="" type="checkbox"/> | Epinephrine hydrochloride : 50 µg/ml Hetastarch : 60 mg/ml | | 1721 |
| | <input checked="" type="checkbox"/> | Epinephrine hydrochloride Hyaluronidase | | 3617 |
| | <input checked="" type="checkbox"/> | Epinephrine hydrochloride Hyaluronidase | | 3184 |
| <input checked="" type="checkbox"/> | <input checked="" type="checkbox"/> | Epinephrine hydrochloride : 100 µg/ml Hydrocortisone sodium succinate : 1 mg/ml | RL | 1228 |
| <input checked="" type="checkbox"/> | <input checked="" type="checkbox"/> | Epinephrine hydrochloride : 128 µg/ml Hydrocortisone sodium succinate : 1 mg/ml | | 4465 |
| <input checked="" type="checkbox"/> | <input checked="" type="checkbox"/> | Epinephrine hydrochloride : 100 µg/ml Hydrocortisone sodium succinate : 1 mg/ml | | 1228 |
| <input checked="" type="checkbox"/> | <input checked="" type="checkbox"/> | Epinephrine hydrochloride : 20 µg/ml Hydromorphone hydrochloride : 1 mg/ml | | 314 |
| | <input checked="" type="checkbox"/> | Epinephrine hydrochloride Hydroxocobalamin | | 3932 |
| <input checked="" type="checkbox"/> | <input checked="" type="checkbox"/> | Epinephrine hydrochloride : 8 >> 100 µg/ml Ibuprofen lysinate : 10 mg/ml | | 4419 |
| <input checked="" type="checkbox"/> | <input checked="" type="checkbox"/> | Epinephrine hydrochloride : 50 µg/ml Imipenem-Cilastatin / Relebactam : 5 mg/ml | | 4433 |
| <input checked="" type="checkbox"/> | <input checked="" type="checkbox"/> | Epinephrine hydrochloride : 60 & 300 µg/ml Insulin aspart : 1 UI/ml | | 1508 |
| <input checked="" type="checkbox"/> | <input checked="" type="checkbox"/> | Epinephrine hydrochloride : 1000 µg/ml Iohexol : 300 mg I/ml | ∅ | 1085 |
| <input checked="" type="checkbox"/> | <input checked="" type="checkbox"/> | Epinephrine hydrochloride : 1000 µg/ml Ioxaglate : 320 mg I/ml | ∅ | 1085 |
| | <input checked="" type="checkbox"/> | Epinephrine hydrochloride Iron (polymaltose) | | 3642 |
| | <input checked="" type="checkbox"/> | Epinephrine hydrochloride Iron dextran | | 3642 |
| <input checked="" type="checkbox"/> | <input checked="" type="checkbox"/> | Epinephrine hydrochloride : 16 µg/ml Isavuconazonium sulfate : 1.5 mg/ml | | 3829 |
| <input checked="" type="checkbox"/> | <input checked="" type="checkbox"/> | Epinephrine hydrochloride : 1000 µg/ml Ketamine hydrochloride : 50 mg/ml | | 2109 |
| <input checked="" type="checkbox"/> | <input checked="" type="checkbox"/> | Epinephrine hydrochloride : 128 µg/ml Labetalol hydrochloride : 5 mg/ml | | 3879 |
| <input checked="" type="checkbox"/> | <input checked="" type="checkbox"/> | Epinephrine hydrochloride : 20 µg/ml Labetalol hydrochloride : 2 mg/ml | | 314 |
| <input checked="" type="checkbox"/> | <input checked="" type="checkbox"/> | Epinephrine hydrochloride : 1000 µg/ml Levofloxacin : 5 mg/ml | | 1072 |
| <input checked="" type="checkbox"/> | <input checked="" type="checkbox"/> | Epinephrine hydrochloride : 1000 µg/ml Levosimendan : 2,5 mg/ml | | 4389 |
| <input checked="" type="checkbox"/> | <input checked="" type="checkbox"/> | Epinephrine hydrochloride : 9 µg/ml Lidocaine hydrochloride : 9 & 18 mg/ml | | 2878 |
| <input checked="" type="checkbox"/> | <input checked="" type="checkbox"/> | Epinephrine hydrochloride : 20 µg/ml Lorazepam : 0.5 mg/ml | | 314 |
| <input checked="" type="checkbox"/> | <input checked="" type="checkbox"/> | Epinephrine hydrochloride : 1000 µg/ml Meropenem : 50 mg/ml | | 4319 |

| | | | | |
|--|--|---|------|------|
| | | Epinephrine hydrochloride : 128 µg/ml Metoprolol tartrate : 0.4 mg/ml | | 3879 |
| | | Epinephrine hydrochloride : 50 µg/ml Micafungin : 1.5 mg/ml | | 2108 |
| | | Epinephrine hydrochloride : 20 µg/ml Midazolam hydrochloride : 2 mg/ml | | 314 |
| | | Epinephrine hydrochloride : 20 µg/ml Milrinone lactate : 0.2 mg/ml | | 314 |
| | | Epinephrine hydrochloride : 32 µg/ml Milrinone lactate : 1 mg/ml | | 4506 |
| | | Epinephrine hydrochloride : 128 µg/ml Milrinone lactate : 0.8 mg/ml | | 813 |
| | | Epinephrine hydrochloride : 20 µg/ml Morphine sulfate : 2 mg/ml | | 314 |
| | | Epinephrine hydrochloride : 1000 µg/ml N-acetylcysteine : 200 mg/ml | | 3766 |
| | | Epinephrine hydrochloride : 1000 µg/ml Naloxone hydrochloride : 0.4 mg/ml | | 3408 |
| | | Epinephrine hydrochloride : 20 µg/ml Nicardipine hydrochloride : 1 mg/ml | | 314 |
| | | Epinephrine hydrochloride : 20 µg/ml Nitroglycerin : 0.4 mg/ml | | 314 |
| | | Epinephrine hydrochloride : 20 µg/ml Norepinephrine bitartrate : 0.128 mg/ml | | 314 |
| | | Epinephrine hydrochloride : 40 µg/ml Oritavancin : 0.8 >>2 mg/ml | | 3152 |
| | | Epinephrine hydrochloride : 4 µg/ml Pancuronium bromide : 0.05 mg/ml | | 402 |
| | | Epinephrine hydrochloride : 16 >> 32 µg/ml Pantoprazole sodium : 0.16 >> 0.8 mg/ml | | 1902 |
| | | Epinephrine hydrochloride Pantoprazole sodium | | 2090 |
| | | Epinephrine hydrochloride : 1 µg/ml Paracetamol : 10 mg/ml | | 4742 |
| | | Epinephrine hydrochloride : 12 µg/ml Pentoxifyllin : 5 mg/ml | | 4543 |
| | | Epinephrine hydrochloride : 16 µg/ml Plazomicin sulfate : 24 mg/ml | | 4145 |
| | | Epinephrine hydrochloride : 100 µg/ml Potassium chloride : 40 mEq/l | | 1228 |
| | | Epinephrine hydrochloride : 100 µg/ml Potassium chloride : 40 mEq/l | RL | 1228 |
| | | Epinephrine hydrochloride : 100 µg/ml Propofol : 10 mg/ml | | 300 |
| | | Epinephrine hydrochloride : 0.1 µg/ml Propofol | | 660 |
| | | Epinephrine hydrochloride : 20 µg/ml Ranitidine hydrochloride : 1 mg/ml | | 314 |
| | | Epinephrine hydrochloride : 50 µg/ml Remifentanil hydrochloride : 25 & 250 µg/ml | | 59 |
| | | Epinephrine hydrochloride : 1 & 10 µg/ml Sodium bicarbonate : 84 mg/ml | | 2077 |

| | | | | |
|---|---|--|--|------|
|  |  | Epinephrine hydrochloride Sodium bicarbonate | | 3086 |
| |  | Epinephrine hydrochloride : 1000 µg/ml Sugammadex : 100 mg/ml |  | 3372 |
| |  | Epinephrine hydrochloride : 0,016 µg/ml Sulbactam/durlobactam : 15/15 mg/ml |  | 4801 |
| |  | Epinephrine hydrochloride : 16 µg/ml Tedizolid phosphate : 0.8 mg/ml |  | 3827 |
| |  | Epinephrine hydrochloride : 50 µg/ml Temocilline : 83.33 mg/ml |  | 2231 |
|  |  | Epinephrine hydrochloride : 20 µg/ml Thiopental sodium : 25 mg/ml | | 314 |
| |  | Epinephrine hydrochloride : 2 & 100 µg/ml Tirofiban : 50 µg/ml |  | 1603 |
| |  | Epinephrine hydrochloride Tirofiban | | 1512 |
| |  | Epinephrine hydrochloride : 50 µg/ml Vancomycin hydrochloride : 10 mg/ml |  | 3385 |
| |  | Epinephrine hydrochloride : 4 µg/ml Vasopressin : 2 & 4 UI/ml |  | 1801 |
| |  | Epinephrine hydrochloride : 20 µg/ml Vecuronium bromide : 1 mg/ml | | 314 |
| |  | Epinephrine hydrochloride : 4 µg/ml Vecuronium bromide : 0.1 mg/ml |  | 402 |
| |  | Epinephrine hydrochloride : 2 µg/ml Verapamil hydrochloride : 0.08 mg/ml |  | 1057 |
| |  | Epinephrine hydrochloride : 100 µg/ml Warfarin sodium : 0.1 & 2 mg/ml |  | 552 |



Voie d'administration



Bibliographie

| | Type | Source |
|-----|-------|--|
| 59 | Revue | Trissel LA, Gilbert DL, Martinez JF, Kim MC. Compatibility of remifentaniol hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2192-2196. |
| 192 | Revue | Peddicord TE, Olsen KM, ZumBrunnen TL, Warner DJ, Webb L. Stability of high-concentration dopamine hydrochloride, norepinephrine bitartrate, epinephrine hydrochloride, and nitroglycerin in 5% dextrose injection. Am J Health-Syst Pharm 1997 ; 54: 1417-1419. |
| 197 | Revue | Allwood MC. The stability of four catecholamines in 5% glucose infusions. J Clin Pharm Ther 1991 ; 16: 337-340. |

| | | |
|------|-------|--|
| 198 | Revue | Gayed AA, Kheshary PR, Hinkle RL. Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 516-520. |
| 217 | Revue | Allen LV, Stiles ML, Wang DP, Tu YH. Stability of bupivacaine hydrochloride, epinephrine hydrochloride, and fentanyl citrate in portable infusion-pump reservoirs. Am J Hosp Pharm 1993 ; 50: 714-715. |
| 280 | Revue | Allen LV, Stiles ML, Prince SJ, Sylvestri MF. Stability of cefpirome sulfate in the presence of commonly used intensive care drugs during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 2427-2433. |
| 299 | Revue | Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741. |
| 300 | Revue | Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292. |
| 314 | Revue | Chiu MF, Schwartz ML. Visual compatibility of injectable drugs used in the intensive care unit. Am J Health-Syst Pharm 1997 ; 54: 64-65. |
| 398 | Revue | Jay GT, Fanikos J, Souney PF. Visual compatibility of famotidine with commonly used critical-care medications during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 1556-1557. |
| 402 | Revue | Savitsky ME. Visual compatibility of neuromuscular blocking agents with various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1990 ; 47: 820-821. |
| 552 | Revue | Martinez JF, Trissel LA, Gilbert DL. Compatibility of warfarin sodium with selected drugs and large-volume parenteral solutions. Int J Pharm Compound 1997 ; 1: 356-358. |
| 659 | Revue | Donnelly RF, Yen M. Epinephrine stability in plastic syringes and glass vials. Can J Hosp Pharm 1996 ; 49: 62-65. |
| 660 | Revue | Michaels MR, Stauffer GL, Haas DP. Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility. Ann Pharmacotherapy 1996 ; 30: 228-232. |
| 813 | Revue | Akkermann SR, Zhang H, Mullins RE, Yaughn K. Stability of milrinone lactate in the presence of 29 critical care drugs and 4 IV solutions. Am J Health-Syst Pharm 1999 ; 56: 63-68. |
| 939 | Revue | Gilbar PJ, Groves CF. Visual compatibility of total parenteral nutrition solution (Synthamin 17 Premix*) with selected drugs during simulated Y-site injection. Aust J Hosp Pharm 1994 ; 24: 167-170. |
| 1041 | Revue | Hasegawa GR, Eder JF. Visual compatibility of dobutamine hydrochloride with other injectable drugs. Am J Hosp Pharm 1984 ; 41: 949-951. |
| 1057 | Revue | Cutie MR. Compatibility of verapamil hydrochloride injection with commonly used additives. Am J Hosp Pharm 1983 ; 40: 1205-1207. |
| 1072 | Revue | Saltsmann CL, Tom CM, Mitchell A, Fan JH, Gailey RA. Compatibility of levofloxacin with 34 medications during simulated Y-site administration. Am J Health-Syst Pharm 1999 ; 56: 1458-1459. |

| | | |
|------|-------------|--|
| 1085 | Revue | Irving HD, Burbridge BE. Incompatibility of contrast agents with intravascular medications. Radiology 1989 ; 173: 91-92. |
| 1201 | Revue | Yuhas EM, Lofton FT, Rosenberg HA, Mayron D, Baldinus JG. Cimetidine hydrochloride compatibility III: Room temperature stability in drug admixtures. Am J Hosp Pharm 1981 ; 38: 1919-1922. |
| 1228 | Revue | Allen LV, Stiles ML. Compatibility of various admixtures at Y-injection sites of intravenous administration sets. Part2. Am J Hosp Pharm 1981 ; 38: 380-381. |
| 1232 | Revue | Beatson C, Taylor A. A physical compatibility study of furosemide & flucloxacillin injections. Br J Pharm Pract 1987 ; 9: 223-226, 236. |
| 1506 | Revue | Lopez-Cabezas C, Guerrero L, Molas G, Anglada H, Soy D. Physicochemical compatibility of high concentration drugs usually Y-site administered in intensive care units. EJHP 2015 ;22:107-112. |
| 1508 | Revue | Voirol P, Berger-Gryllaki M, Pannatier A, Eggimann P, Sadeghipour F. Visual compatibility of insulin aspart with intravenous drugs frequently used in ICU. EJHP 2015 ;22:123-124. |
| 1512 | Laboratoire | Tirofiban (Aggrastat®) - Summary of Product Characteristics Beacon Pharmaceuticals Ltd 2015 |
| 1603 | Revue | Bergquist PA, Manas D, Hunke WA, Reed RA. Stability and compatibility of tirofiban hydrochloride during simulated Y-site administration with other drugs. Am J Health-Syst Pharm 2001 ; 58: 1218-1223. |
| 1611 | Revue | Chalmers JR, Bobek MB, Militello MA. Visual compatibility of amiodarone hydrochloride injection with various intravenous drugs. Am J Health-Syst Pharm 2001 ; 58: 504-506. |
| 1712 | Revue | Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233. |
| 1713 | Revue | Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315. |
| 1721 | Revue | Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72. |
| 1801 | Revue | Feddema S, Rusho WJ, Tyler LS, Barker B. Physical compatibility of vasopressin with medications commonly used in cardiac arrest. Am J Health-Syst Pharm 2003 ; 60: 1271-1272. |
| 1803 | Revue | Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85. |
| 1875 | Revue | Kjonnixsen I, Brustugun J, Breivik H, Anderssen E, Klem W. Stability of an epidural analgesic solution containing adrenaline, bupivacaine and fentanyl. Acta Anaesthesiol Scand 2000 ; 44: 864-867. |
| 1902 | Revue | Walker SE, Wyllie A, Law S. Physical compatibility of pantoprazole with selected medications during simulated Y-site administration. Can J Hosp Pharm 2004 ; 57, 2: 90-96. |
| 1965 | Revue | Brustugun J, Kristensen S, Tonnesen HH. Photostability of sympatomimetic agents in commonly used infusion media in the absence and presence of bisulfite. PDA J Pharm Sci Technol 2004 ; 58, 6: 296-308. |

| | | |
|------|-------------|---|
| 1982 | Revue | Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837. |
| 2018 | Revue | Veggeland T. Visual compatibility of clonidine with selected drugs. Am J Health-Syst Pharm 2005 ; 62: 1968-1969. |
| 2077 | Revue | Bonhomme L, Benhamou D, Comoy E, Preaux N. Stability of epinephrine in alkalized solutions. Ann Emerg Med 1990 ; 19: 1242-1244. |
| 2089 | Revue | Brustugun J, Kristensen S, Tonnesen HH. Photostability of epinephrine - the influence of bisulfite and degradation products. Pharmazie 2004 ; 59: 457-463. |
| 2090 | Revue | Pere H, Chasse V, Forest JM, Hildgen P. Compatibility of injectable pantoprazole in Y-site administration. Pharmactuel 2004 ; 37: 193-196. |
| 2108 | Revue | Trusley C, Kupiec TC, Trissel LA. Compatibility of micafungin injection with other drugs during simulated Y-site co-administration. Int J Pharm Compound 2006 ; 10: 230-232. |
| 2109 | Revue | Pelletier E, Forest JM, Hildgen P. Compatibilité de la kétamine injectable lors de l'administration en dérivé avec d'autres médicaments usuels. Pharmactuel 2006 ; 39: 71-75. |
| 2141 | Revue | Barinian N, Chanteux H, Viaene E, Servais H, Tulkens PM. Stability and compatibility study of cefepime in comparaison with ceftazidime for potential administration by continuous infusion under conditions pertinent to ambulatory treatment of cystic fibrosis patients and to administration in intensive care units. J Antimicrob Chemother 2003 ; 51: 651-658. |
| 2231 | Revue | de Jongh R, Hens R, Basma V, mouton JW, Tulkens PM, Carryn S. Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection. J Antimicrob Chemother 2008 ; 61, 2: 382-388. |
| 2247 | Revue | Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278. |
| 2306 | Revue | Priston M.J, Hughes J.M, Santillo M, Christie I.W. Stability of an epidural analgesic admixture containing epinephrine, fentanyl and bupivacaine. Anaesthesia 2004 ; 59, 10: 979-983. |
| 2878 | Revue | Pascuet E, Donnelly RF, Garceau D, Vaillancourt R. Buffered Lidocaine Hydrochloride Solution With and Without Epinephrine: Stability in Polypropylene Syringes. Can J Hosp Pharm 2009 ; 62, 5: 375-380. |
| 3012 | Revue | Sullivan T, Forrest J.M, Leclair G. Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration Hosp Pharm 2015 ; 50, 3: 214-220. |
| 3086 | Revue | Robinson, J, Fernando, R, Sun Wai, W.Y., Reynolds, F. Chemical stability of bupivacaine, lidocaine and epinephrine in pH-adjusted solutions. Anaesthesia 2000 ; 55, 9: 853-858. |
| 3152 | Revue | Kumar A, Mann HJ. Visual compatibility of oritavancin diphosphate with selected coadministered drugs during simulated Y-site administration. Am J Health-Syst Pharm 2010 ; 67: 1640-1644. |
| 3184 | Laboratoire | Hyaluronidase (Hyalase®) - Summary of Product characteristics. CP Pharmaceuticals 2005 |

| | | |
|------|-------------|--|
| 3210 | Revue | Jasti Bhaskara R, Saraf Poonam. Compatibility of Parenteral Furosemide with Seventeen Secondary Drugs Used in Standard Concentrations. Int J Pharm Compound 2011 ; 15, 3: 259-261. |
| 3309 | Revue | Zenoni D, Priori G, Bellan C, Invernizzi R.W. Stability of diluted epinephrine in prefilled syringes for use in neonatology. EJHP 2012 ;19:378-380 |
| 3372 | Revue | Hanci V, Ali Kiraz H, Ömür D, Ekin S, Uyan B, Yurtlu B.S. Precipitation in Gallipoli: Sugammadex / Amiodarone & Sugammadex / Dobutamine & Sugammadex / Protamine. Rev Bras Anesthesiol 2013 ; 63, 1: 163-166. |
| 3379 | Revue | Fox L.M, Wilder A.G, Foushee J.A. Physical compatibility of various drugs with neonatal total parenteral nutrient solution during simulated Y-site administration. Am J Health-Syst Pharm 2013 ;70:520-524. |
| 3385 | Revue | Raverdi V, Ampe E, Hecq JD, Tulkens PM. Stability and compatibility of vancomycin for administration by continuous infusion. J Antimicrob Chemother 2013 ; 68: 1179-1182. |
| 3397 | Poster | Heeb R.M, Krämer I. Physicochemical stability of ready-to-administer epinephrine injection solutions 20 µg/mL, 50 mL. EAHP Congress Paris 2013 |
| 3401 | Revue | Helin-Tanninen, M., Lehtonen, M., Naaranlahti, T., Ven?inen, T., Pentik?inen, J., Laatikainen, A., Kokki, H. Stability of an epidural analgesic admixture of levobupivacaine, fentanyl and epinephrine. J Clin Pharm Ther 2013 ;38, 2: 104-108 |
| 3408 | Revue | Tollec S, Touzin K, Pelletier E, Forest J.M. Evaluation visuelle de la compatibilité physique de la naloxone avec d'autres médicaments intraveineux usuels. Pharmactuel 2013 ; 46, 1 : 16-21. |
| 3420 | Revue | El Kateb N, Chaussard M, Bellenger P, Petit A, Faure P. Stability of an extemporaneously prepared bleomycin-lidocaine-epinephrine intradermal admixture used in dermatology J Oncol Pharm Practice 2014 ; 21, 3: 178-187. |
| 3445 | Revue | Heeb R.M, Thiesen J, Krämer I. Aseptische Herstellung applikationsfertiger Adrenalin-Dauerinjektionen 20 µg/ml. Krankenhauspharmazie 2013 ; 34, 8: 410-411. |
| 3617 | Laboratoire | Hyaluronidase (Hyalase®) - Summary of Product Characteristics Wockhardt 2011 |
| 3622 | Revue | Weeks Phillip A, Teng Yang, Wu Lei, Sun Mary, Yang Zhen, Chow Diana S-L. Chemical and Physical Compatibility of an Intravenous Solution of Epinephrine with Calcium Chloride. Int J Pharm Compound 2014 ; 18, 2 : 152-158. |
| 3642 | Laboratoire | Epinephrine - Résumé des Caractéristiques du Produit International Medication System (UK) 2013 |
| 3704 | Revue | Carr R.R, Decarie D, Ensom M.H.H Stability of Epinephrine at Standard Concentrations Can J Hosp Pharm 2014 ; 67, 3:179-202. |
| 3712 | Revue | Ghanayem N.S, Lee L, Nelson T, Wong S, Gordon G.B, Markdante K et al. Stability of dopamine and epinephrine solutions up to 84 hours. Pediatr Crit Care Med 2001 ; 2, 4: 315-317. |
| 3766 | Revue | Forrest J.M, Hildgen P. Compatibilité de l'acétylcystéine injectable lors de son administration en Y avec d'autres médicaments usuels Pharmactuel 2014 ; 47, 3 : 161-165. |
| 3824 | Revue | Boudi S, Roy H, Forest JM, Leclair G. Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y. Pharmactuel 2023 2023;56,3:91-98 |

| | | |
|------|-------------|--|
| 3827 | Poster | Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015 |
| 3828 | Poster | Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015 |
| 3829 | Poster | So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015 |
| 3879 | Revue | Foushee Jaime A, Meredith Pmichaele, Fox Laura M, Grace Edward E. Y-site Physical Compatibility of Beta-blocker Infusions with Intensive Care Unit Admixtures. Int J Pharm Compound 2016 ; 20, 4 : 328-332. |
| 3932 | Laboratoire | Hydroxocobalamine (Cyanokit®) - Résumé des caractéristiques du produit Serb Laboratoire 2015 |
| 3964 | Revue | Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G. Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments. Pharmactuel 2017 ; 50,1 : 27-33. |
| 4026 | Revue | Van Matre E.T, Ho K.C., Lyda C, Fullmer B.A, Oldlan A.R, Kiser T.H. Extended Stability of Epinephrine Hydrochloride Injection in Polyvinyl Chloride Bags Stored in Amber Ultraviolet Light-Blocking Bags. Hosp Pharm 2017 ; 52, 8 : 570-573 |
| 4055 | Revue | Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44 |
| 4145 | Revue | Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056 |
| 4319 | Revue | Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337. |
| 4323 | Poster | Wethmar U, Hochbrügge H, Strobel HG. Stabilitätsprüfung von applikationsfertigen Adrenalin- und Noradrenalinverdünnungen. ADKA Kongress 2019 |
| 4389 | Revue | Côté K, Correal F, Metras M.E, Friciu M, Forest J.M, Leclair G. Compatibilité physique des médicaments administrés en Y aux soins intensifs, en particulier la dexmédétomidine, le lévოსимendan et la kétamine. Pharmactuel 2019 ;52,4:206-213 |
| 4393 | Poster | Hook R, Riss V, Neault A, Ma N, Law S, Walker S.E. Chemical Stability of Epinephrine Diluted in 0.9% Sodium Chloride and Stored in Polypropylene (PP) Syringes at 4°C and 25°C. Sunnybrook Health Sciences Centre 2020 |
| 4419 | Revue | Holt R.J, Siegert S.W.K, Krishna A. Physical Compatibility of Ibuprofen Lysine Injection with Selected Drugs During Simulated Y-site Injection. J Pediatr Pharmacol Ther 2008 ; 13, 3: 155-161. |
| 4433 | Revue | Ghazi I.M, El Nekidy W.S, Sood A, Dulku A, Patel R, Patel K. Y-site Administration of Imipenem/Cilastatin/ Relebactam With Common Intravenous Medications Clin Ther 2020 ; 42, 3: 475-485. |
| 4434 | Revue | Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L. Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration. Clin Ther 2019 ; 41, 10: 2162-2170. |

| | | |
|------|-------|---|
| 4465 | Revue | Foushee A, Meredith P, Fox Laura, Wilder A. Y-site physical compatibility of hydrocortisone continuous infusions with admixtures used in critically ill patients. Am J Health-Syst Pharm 2020 ;77,14:1144-1148 |
| 4491 | Revue | De Basagoiti A, Katsumiti A, Abascal S, Bustinza A, López-Giménez L.R, Pilar P, De Miguel M, Campino A. Physical compatibility of alprostadil with selected drugs commonly used in the neonatal intensive care units. Eur J Pedia 2020 |
| 4506 | Revue | Griffith S, Stapleton E, Padilla S, Mruk A, Thomas C. Physical compatibility of milrinone 1 mg/mL with select cardiovascular medications during simulated Y-site administration. Am J Health-Syst Pharm 2020 ;77,23:1938-1940. |
| 4528 | Revue | Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61 |
| 4543 | Revue | Senarathna G, Strunk T, Petrovski M, Batty K. Physical compatibility of pentoxifylline and intravenous medications. Archives of Disease in Childhood 2018 ;104:292–295. |
| 4570 | Revue | Greenhill K, Hornsby E, Gorman G. Investigations of Physical Compatibilities of Commonly Used Intravenous Medications with and without Parenteral Nutrition in Pediatric Cardiovascular Intensive Care Unit Patients. Pharmaceuticals 2019 |
| 4603 | Revue | Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G. Compatibility of Lactated Ringer's Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration. Hosp Pharm 2021 ; 56, 4: 228-234. |
| 4651 | Revue | De Basagoiti A, Katsumiti A, Abascal S, Bustinza A, López-Giménez L.R, Pascual P, De Miguel M, Campino A. Physical compatibility of alprostadil with selected drugs commonly used in the neonatal intensive care units. Eur J Pedia 2021 ;180,1169–1176. |
| 4655 | Revue | Holyk A, Lindner A, Lindner S, Shippert B Physical compatibility of Normosol-R with critical care medications used in patients with COVID-19 during simulated Y-site administration. Am J Health-Syst Pharm 2022 ;79,1:27-33 |
| 4732 | Revue | Kenneally A, Agbana P, Gardner B, Bae Y, Mitchell T, Beckman E. Compatibility of calcium chloride with milrinone, epinephrine, vasopressin, and heparin via in vitro testing and simulated Y-site administration. Am J Health-Syst Pharm 2023 80, 3:164–170 |
| 4742 | Revue | Macoviciuc M, Nguyen C, Forest J-M, Leclair G. Compatibilité physique de l'acétaminophène injectable avec 102 autres médicaments lors d'une administration en Y. Pharmactuel 2022 ; 55, 4: 247-255. |
| 4778 | Revue | Hook R, Neault A, Scharer D, Law S, Walker S.E, Ma N.H, Riss V. Chemical stability of epinephrine 10 µg/mL diluted in 0.9% sodium chloride and stored in polypropylene syringes at 4°C and 25°C. Int J Pharm Compound 2023 ; 27, 4: 347-351. |
| 4801 | Revue | Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1: |



Dictionnaire

| | | | |
|--|----------------------------------|-----------|---|
| | Sympathomimétique | | Injectable |
| | Noms commerciaux | | Stabilité des solutions |
| | Contenant | | Molécule |
| | Concentration | | Température |
| | Conservation | | Durée de stabilité |
| | Biosimilaire | | Données conflictuelles |
| | Bibliographie | | Verre |
| | Eau pour préparation injectable | | A l'abri de la lumière |
| | Jour | | Polyvinyl chlorure |
| | Chlorure de sodium 0,9% | | Lumière |
| | Glucose 5% | | Heure |
| | Seringue polypropylène | | NaCl 0,9% ou glucose 5% |
| | Non précisée | | Glucose 10% |
| | Seringue polycarbonate | | Non précisé |
| | Stabilité en mélange | | Solvant |
| | Molécule | RL | Ringer lactate |
| | Chlorure de sodium 0,45% | | Non précisé |
| | Polypropylène | | Aucun |
| | Avec ou sans lumière | | Facteur influençant la stabilité |
| | Provoque | | Dégradation |
| | Augmentation stabilité | | NaHCO3 |
| | Augmentation | | Compatibilités |
| | Compatible | | Normosol® |
| | Instabilité chimique | | Incompatible |
| | Incompatibilité non précisée | | Nutrition parentérale (mélange binaire) |
| | Solvant spécifique | | Précipitation en 4 heures |
| | Précipitation immédiate | | Instabilité de l'émulsion à 6 heures |
| | Changement de couleur à 4 heures | | Voie d'administration |
| | Intraveineuse | | Perfusion intraveineuse |
| | Intramusculaire | | Sous cutanée |



Intracardiaque



Bibliographie



Dictionnaire